



Iveric Bio to Present at the 2020 Webbush PacGrow Healthcare Virtual Conference

August 4, 2020

NEW YORK--(BUSINESS WIRE)--Aug. 4, 2020-- [IVERIC bio, Inc.](#) (Nasdaq: ISEE) announced today that Pravin U. Dugel, MD, Executive Vice President and Chief Strategy and Business Officer, will present an overview of the Company at the Webbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10 a.m. Eastern Time.

Investors and the general public are invited to listen to a live webcast of the presentation available on the Investor / Events & Presentations section of the IVERIC bio website at www.ivericbio.com. An archived replay of the webcast will be available on the Company's website immediately following the conference and for at least two weeks thereafter.

About IVERIC bio

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about IVERIC bio's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio's views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.

ISEE-G

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200804005003/en/): <https://www.businesswire.com/news/home/20200804005003/en/>

Investor Contact:

IVERIC bio
Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com

or

Media Contact:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: IVERIC bio, Inc.